[HTML][HTML] Triple‑negative breast cancer therapy: Current and future perspectives
KA Won, C Spruck - International journal of …, 2020 - … .spandidos-publications.com
Triple‑negative breast cancer (TNBC) accounts for 10‑15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
Triplenegative breast cancer therapy: Current and future perspectives
KA Won, C Spruck - International Journal of Oncology, 2020 - ingentaconnect.com
Triplenegative breast cancer (TNBC) accounts for 1015% of all breast cancer cases. TNBCs
lack estrogen and progesterone receptors and express low levels of HER2, and therefore do …
lack estrogen and progesterone receptors and express low levels of HER2, and therefore do …
Triple-negative breast cancer therapy: Current and future perspectives
KA Won, C Spruck - International Journal of Oncology, 2020 - go.gale.com
Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
[HTML][HTML] Triple‑negative breast cancer therapy: Current and future perspectives
KA Won, C Spruck - International Journal of Oncology, 2020 - spandidos-publications.com
Triple‑negative breast cancer (TNBC) accounts for 10‑15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
[HTML][HTML] Triple-negative breast cancer therapy: Current and future perspectives
KA Won, C Spruck - International Journal of Oncology, 2020 - ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
[引用][C] Triple‑negative breast cancer therapy: Current and future perspectives
KA Won, C Spruck - International Journal of Oncology, 2020 - cir.nii.ac.jp
Triple‑negative breast cancer therapy: Current and future perspectives (Review) | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Triple-negative breast cancer therapy: Current and future perspectives
KA Won, C Spruck - International Journal of Oncology, 2020 - search.ebscohost.com
Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
Triple‑negative breast cancer therapy: Current and future perspectives
KA Won, C Spruck - International Journal of Oncology, 2020 - europepmc.org
Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
Triple‑negative breast cancer therapy: Current and future perspectives
KA Won, C Spruck - International journal of oncology, 2020 - pubmed.ncbi.nlm.nih.gov
Triple‑negative breast cancer (TNBC) accounts for 10‑15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
Triple-negative breast cancer therapy: Current and future perspectives
C Spruck - International Journal of Oncology, 2020 - search.proquest.com
Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …